Showing results (21-30 of 157) with videos related to
Sort By:
Pageof 16
European Journal of Clinical Pharmacology|June 8, 2006
Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeineJanne T Backman, Marika T Granfors, Pertti J NeuvonenEuropean Journal of Clinical Pharmacology|October 24, 2007
Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidineJanne T Backman, Marika T Schröder, Pertti J NeuvonenClinical Pharmacology and Therapeutics|June 18, 2003
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearanceCarl Kyrklund, Janne T Backman, Mikko Neuvonen, et al.Pharmacology Research & Perspectives|June 4, 2021
Health service use and costs associated with fluoroquinolone-related tendon injuriesLaura S M Kuula, Janne T Backman, Marja L BlomBritish Journal of Clinical Pharmacology|January 30, 2004
Effect of rifampicin on pravastatin pharmacokinetics in healthy subjectsCarl Kyrklund, Janne T Backman, Mikko Neuvonen, et al.Clinical Pharmacology and Therapeutics|March 28, 2019
Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and InterpretationAleksi Tornio, Anne M Filppula, Mikko Niemi, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 23, 2011
Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil dosesJohanna Honkalammi, Mikko Niemi, Pertti J Neuvonen, et al.Pharmacology Research & Perspectives|February 16, 2022
Healthcare costs and mortality associated with serious fluoroquinolone-related adverse reactionsLaura S M Kuula, Janne T Backman, Marja L BlomClinical Pharmacology and Therapeutics|May 19, 2005
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazoneTiina Jaakkola, Janne T Backman, Mikko Neuvonen, et al.Basic & Clinical Pharmacology & Toxicology|July 27, 2006
Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitorsTiina Jaakkola, Jouko Laitila, Pertti J Neuvonen, et al.Pageof 16